MEETING ABSTRACTS Open Access Abstracts from the First European Meeting for ATTR Amyloidosis for Doctors and Patients Paris, France. 02-03 November 2017 Published: 2 November 2017 Introduction David Adams 1 , Philip Hawkins 2 , Hartmut Schmidt 3 1 Department of Neurology, NNERF, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, Paris-Sud University, Le Kremlin-Bicêtre, France; 2 National Amyloidosis Centre, Division of Medicine, University College London, London, UK; 3 University Hospital of Muenster, Muenster, Germany ATTR amyloidosis comprises a group of rare multisystem diseases including non-hereditary wild type ATTR amyloidosis (also known as senile cardiac amyloidosis, senile systemic amyloidosis), Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC). FAP was first described in the 1950s in Portugal presenting as autosomal dominant disease, whereas wild type ATTR amyloidosis was recognized in the 1980s as a non-hereditary form of restrictive cardiomyopathy in older patients. ATTR amyloidoses are global diseases that are now being identified in most countries. They are progressive and life-threatening, and diagnosis is usually delayed. The First European meeting for ATTR amyloidosis for doctors and patients (Fig. 1) will inaugurate a new era in relations between patients, between doctors, and between doctors and patients from many European coun- tries with the ultimate aim of improving diagnosis, treatment and care of this serious disease. Advocacy and Education experts from international institutions in- cluding EURORDIS (the Voice of Rare Disease Patients in Europe), ARC (Amyloidosis Research Centre), and the ISA (International Society of Amyloidosis) will be present. Since it is the first event of this nature, we propose three intercon- nected meetings over the course of two days. On Day One, Patients and Doctors will each have their own meeting; on Day Two, Patients and Doctors will share a common session. During the meeting for specialists, six keynote lectures and 59 abstracts will be presented, comprising 11 oral communications and 48 posters. Final data from two major phase 3 clinical trials for TTR-FAP will be presented. Eleven national Patients’ Organizations will participate. Attendees will in- clude specialists predominantly from Europe but also from USA, South America and Asia. Fig. 1. Conference poster Orphanet Journal of Rare Diseases 2017, 12(Suppl 1):165 DOI 10.1186/s13023-017-0710-5 © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.